DMSA: the oral chelator, explained honestly
DMSA mainly binds lead, acts largely in the extracellular space and can also carry trace elements out with it. What the molecule can do, where its limits are and why oral does not mean harmless.
Where DMSA belongs in the heavy-metal cluster
This text is a tool spoke. You will find the broad overview of all metals, diagnostics and the logic of a detox in the heavy-metal overview. Here it is purely about one molecule: DMSA, the oral chelator. Its pharmacokinetics, its lead focus, the self-medication trap and the dosing controversy. If a paragraph could just as well sit in the overview, it does not belong here.
The capsule in the shopping cart
Many people know this moment. You read somewhere that heavy metals can be cleared out "gently and orally". You type "buy DMSA" or "DMSA capsules reviews" into the search bar. A few clicks later a pack is in your shopping cart, somewhere between magnesium and vitamin D, as if it were exactly the same thing.
At this point I do not want to moralize. I want to explain what this molecule pharmacologically really is. Because the seemingly harmless oral form raises exactly the question that gets lost in the shopping cart: if DMSA can act at all, then it is a drug. And if it is a drug, then it has a profile that you should know before you take it.
DMSA is not a supplement you toss in on the side. It is a thiol-bearing active substance that binds metals and routes them out through the kidney. The very property that can make it useful also makes it something that needs diagnostics and monitoring. "Oral" describes the route into the body, not the strength of the effect.
First a clarification: which DMSA is meant?
The abbreviation DMSA is ambiguous. In nuclear medicine, "DMSA scintigraphy" refers to a kidney examination with a radioactively labelled substance. In the IT world, "DMSA" means an account type on Windows servers. Neither has anything to do with this article.
Here it is about the active substance meso-2,3-dimercaptosuccinic acid, internationally also called succimer. This is an oral chelator, that is a molecule that grips metals in a kind of chemical pincer and carries them out of the body via the urine. Whenever DMSA is mentioned below, this molecule is always meant.
What DMSA does in the body, step by step
To understand what DMSA can and cannot do, it helps to look at its path through the body. That path is remarkably well described and differs clearly from what many people expect. Unlike the intravenous sibling molecule DMPS, whose mechanism we take apart in the DMPS spoke, DMSA works from the first minute under the conditions of the gut and the blood plasma.
Uptake through the gut
DMSA is swallowed as a capsule and only incompletely absorbed from the gut. A substantial part remains in the digestive tract, which co-determines gastrointestinal tolerability and explains why the oral route has its own logic.
Binding to albumin, staying outside the cells
In the blood, most of the DMSA is protein-bound through a disulfide bond with cysteine, mainly to albumin. It therefore stays largely in the extracellular space. It barely enters the cells or crosses the blood-brain barrier. This is the key to almost everything that follows.
Chelation mainly in the kidney
The actual gripping process appears to take place very largely in the kidney. There, DMSA forms a mixed disulfide with the amino acid cysteine, and in this complex the metal is captured. The chelation is therefore kidney-centred, not spread across the whole body.
Excretion via a transporter into the urine
The finished DMSA-metal complex can be released into the urine via a transporter called MRP2. This route has so far been shown mainly in the rat model and in isolated membranes, in humans it is plausible but not directly proven. With that the picture closes: take up, transport in the plasma, grip in the kidney, excrete via the urine.
This systematic appraisal screened over 900 papers on DMSA in inorganic lead poisoning. The picture is well describable: DMSA is incompletely absorbed, is largely protein-bound in plasma, accumulates in the kidney and chelates primarily renal lead there. About 10 to 25 percent of an oral dose appears in the urine, mostly as a DMSA-cysteine conjugate. For you this means: DMSA works mainly in the kidney and in the space outside the cells, which explains its narrow but defined field of action. The side effects are mostly mild and reversible, the limits of the molecule are real.
Bradberry S, Vale A. Clin Toxicol (Phila). 2009;47(7):617-31. DOI: 10.1080/15563650903174828One number that appears in many texts deserves to be set straight: the frequently cited figure of about 90 percent protein binding comes from studies with radioactively labelled scintigraphy DMSA in trace doses, not with the active substance in a therapeutic dose. The direction holds, the exact figure transfers to the active substance only to a limited extent.
And now you know why DMSA is so specific: a molecule that travels almost only outside the cells and does its work in the kidney can act strongly exactly where metals sit accessibly in the blood and the connective tissue. And it can do little where they sit deep inside cells or in the brain.
The most important correction: DMSA is the lead chelator
Many people lump DMSA and DMPS together, as if they were interchangeable. Online you often read that DMSA is the oral agent for mercury detox. This idea is misleading. DMSA has a clear preference, and that is lead.
What DMSA fits best for (binding strength, simplified)
Schematic depiction of the clinical priorities, not exact binding constants. The order lead before arsenic before mercury rests on human data (lead) and largely on animal models (mercury).
The official approval reflects this. In the United States, DMSA, there called succimer, is approved for the treatment of childhood lead poisoning, and specifically from a blood lead level above 45 µg/dL. The range below that, which the TLC trial discussed shortly is about, is expressly not covered by this approval. DMSA is not approved for mercury and not for a general "detox". In Germany, as described above, there is no authorised medicinal product at all. We deliberately do not spread out the sources and symptoms of a lead burden here, that belongs in the spoke on lead poisoning. Here it is only about the tool.
14 patients with heavy-metal poisoning received DMSA. In the nine lead cases, blood lead fell by 35 to 81 percent and mean daily urinary lead excretion rose 4.5- to 16.9-fold. In the three mercury cases, daily urinary mercury excretion rose 1.5-, 2.8- and 8.4-fold, while blood mercury was below the detection limit from the start and therefore could not be evaluated. The authors saw in this a reason to investigate DMSA further in mercury and arsenic. For you this means: the data on lead are far clearer than on mercury. The view that DMSA works less well than DMPS for mercury rests mainly on animal data so far, not on this case series.
Fournier L et al. Med Toxicol Adverse Drug Exp. 1988;3(6):499-504. DOI: 10.1007/BF03259898So if you primarily want to address mercury, for example after years of amalgam exposure, intravenous DMPS may be the better fit. That assessment rests largely on animal models, however, not on a controlled comparison in humans. More on this in the mercury spoke and in the DMPS spoke. Seen through a toxicological lens, this can be less a matter of taste than a question of the affinity and accessibility of the metal.
In a direct comparison in rats, DMPS markedly lowered the mercury content of kidney and liver and increased excretion, while DMSA did not do so in this model. Both form complexes that are excreted via the same transporter. For you this means: for mercury, DMPS can be mechanistically superior to oral DMSA, though this statement rests on animal data.
Bridges CC et al. J Pharmacol Exp Ther. 2007;324(1):383-90. DOI: 10.1124/jpet.107.130708 AnimalDoes DMSA reach the brain?
This is one of the most important and most frequently misunderstood questions. If someone hopes to pull metals out of the brain with DMSA, one has to be honest: the molecule barely gets there. The very property that can make some side effects inside the cells less likely, namely the strong protein binding and the distribution outside the cells, also keeps it away from the brain and the interior of cells.
Safety advantage and limit of action in one
Because DMSA barely enters cells and barely reaches the brain, it can do little harm there, but also retrieve little. That is not a contradiction but the same coin from two sides. If you want a realistic expectation, you should understand DMSA as a tool for readily accessible compartments, not as a deep cleaner of the nervous system.
A low brain penetration protects against some side effects and at the same time limits the reach.
8%In mercury-loaded young rats, DMSA lowered mercury in the kidney by about 48 percent, but in the brain only by about 8 percent. More fat-soluble related molecules reached much more in the brain. For you this means: the low brain penetration of DMSA is well documented, though in an animal model, and it is advantage and limit at the same time.
Kostial K et al. Pharmacol Toxicol. 1995;77(3):216-8. DOI: 10.1111/j.1600-0773.1995.tb01015.x AnimalIn chronic arsenic poisoning in rats, DMSA had an effect but was limited by its water-loving, cell-repelling nature. Only the combination with a fat-soluble analogue removed arsenic from the cells more effectively. For you this means: with arsenic too, DMSA can help, but its extracellular character limits access to deposits inside the cells (animal data).
Bhadauria S, Flora SJS. Cell Biol Toxicol. 2006;23(2):91-104. DOI: 10.1007/s10565-006-0135-8 AnimalWhat the large lead study shows, and what it does not
The most robust human evidence on DMSA comes from a large, cleanly built study in lead-burdened toddlers, the so-called TLC trial with 780 children. It is important because it shows two things at once, both of which you have to sit with.
Toddlers with moderately elevated blood lead received up to three courses of oral DMSA or a dummy preparation, followed by extensive developmental tests. Blood lead fell more under DMSA in the first months. After three years, however, the mean IQ was even minimally lower, and no developmental test came out significantly better. For you this means: DMSA can lower the lead value. The authors found no added mental benefit, and they draw a clear consequence from that. In their own wording, chelation therapy is not indicated for children with blood lead levels in this range. That is a statement I let stand here, uncomfortable as it is.
Rogan WJ et al. N Engl J Med. 2001;344(19):1421-6. DOI: 10.1056/NEJM200105103441902A falling lab value is not automatically a gain
That is the honest lesson from this study. A number in the lab can improve without well-being or development moving along to the same degree. In severe lead poisoning the indication looks different, there the lowering is a clear treatment mandate. At moderate burden the TLC trial dampens the expectation.
Treat the person, not just the lab value.
The same group analysed safety and course. Under DMSA the lead level fell rapidly and then rose again, a so-called rebound. Scalp rashes occurred somewhat more often, 3.5 versus 1.3 percent. Striking in addition was an unanticipated excess of trauma in the succimer group, which the authors themselves classify as requiring confirmation. For you this means: oral is neither without effect nor harmless, the effect is real, but limited in time and needs monitoring.
TLC Trial Group. Pediatr Res. 2000;48(5):593-9. DOI: 10.1203/00006450-200011000-00007Why the value rises again after the course
The rebound is presumably not a failure of the agent but storage mathematics. By far the largest part of a person's lead burden does not sit in the blood but in the bone, there with a half-life of many years. DMSA grips mainly the readily accessible lead in kidney, blood and soft tissue. When the level falls there, lead can flow out of the bone to follow. That could explain why a single course lowers the value only temporarily.
With repeated DMSA courses in lead-burdened children, blood lead fell sharply but rose back to about 58 percent of the baseline value two to three weeks after the end of therapy. Zinc and copper were not driven out to any relevant degree. For you this means: without source avoidance and follow-up monitoring the value can bounce back, a single course rarely suffices.
Chisolm JJ. J Toxicol Clin Toxicol. 2000;38(4):365-75. DOI: 10.1081/clt-100100945In a dose-response study, researchers compared three DMSA doses with intravenous CaNa2EDTA in lead-burdened children. The highest DMSA dose lowered lead more strongly than CaNa2EDTA. The groups were tiny, however, five against six children over seven days. EDTA drove zinc, copper, iron and calcium out via the urine, while DMSA barely did. For you this means: DMSA can be the more mineral-sparing tool. For a robust claim of superiority in lowering lead, a study of this size is not enough.
Graziano JH et al. J Pediatr. 1988;113(4):751-7. DOI: 10.1016/s0022-3476(88)80396-2DMSA, DMPS or EDTA, a quick comparison
Three chelators are often named in one breath, even though they are different tools. Here only the essentials for telling them apart, each with a link into the relevant spoke. The detailed mechanism of intravenous DMPS deliberately does not sit here.
Both bind lead. The practical difference: DMSA is oral and is considered more mineral-sparing, EDTA is given intravenously and drives out more essential minerals. In Graziano's children's comparison, the highest DMSA dose lowered lead more strongly than CaNa2EDTA, with five against six children over seven days. The large comparative review by the same group concludes in 2009 that the data are insufficient to conclude that either agent is superior. What holds: both lower zinc and copper, EDTA the zinc considerably more. The vascular and heart question around EDTA is a story of its own that belongs in the EDTA spoke.
DMSA is a systemic drug that grips metals in the blood and in the kidney. Plant-based approaches such as chlorella, coriander or wild garlic act, by what we know so far, largely in the gut. They can bind metals there that are passing through the gut. That they also pull metals out of the tissue into the blood and onward out of the body has not been convincingly shown so far. A pharmacological chelator starts at a different point. In my view that is not a gradual but a fundamental difference in the point of attack. If you want to place the natural agents in context, you will find that in the spoke on natural heavy-metal detox.
The Cutler protocol, placed in context factually
In forums and personal accounts a popular lay protocol keeps coming up, named after Andrew Cutler. It recommends very frequent doses in small amounts, spread over day and night. Before I place that in context, one sentence belongs first: what is described there is weeks of self-administration of a prescription-only active substance that is not authorised in Germany, without diagnostics, without liver values, without a blood count, without mineral monitoring and often without the source of the burden having been dealt with at all. I deliberately do not give any doses here. The reasoning behind the protocol still deserves a fair presentation before one places it in context.
The idea: DMSA has a short half-life. If you let the level drop sharply between doses, mobilized metal might be redistributed again instead of being excreted. Through very frequent small doses the level is meant to stay constant and this redistribution to be avoided. The rebound that the studies by Rogan and Chisolm also show is drawn on as support for this reasoning.
Mechanistically the idea is debatable, not absurd. But it is not robustly proven. There is no controlled clinical trial that tests the frequent low-dose administration against the approved dosing and shows an advantage. That leaves the Cutler protocol a hypothesis that orients itself to a real phenomenon but has not proven its clinical added value.
I think it is fair to take the argument seriously and at the same time to say clearly: frequent self-administration without diagnostics and monitoring can produce more unrest and more mineral loss than benefit. That is not a put-down of the people who proceed this way, but an honest account of the data.
A Cochrane review examined chelation therapy in children with autism spectrum disorder in 2015, that is expressly without a toxicological indication, among other things with oral DMSA. Only a single study with methodological weaknesses met the criteria, and a clinical benefit could not be shown. At the same time the authors point to documented serious events with chelation therapies in this context, including hypocalcaemia, renal impairment and one reported death. For you this means: without a clear toxicological indication there is no proven benefit for chelation therapy, but there are proven risks.
James S et al. Cochrane Database Syst Rev. 2015;(5):CD010766. DOI: 10.1002/14651858.CD010766Safety and monitoring: what is missing in the shopping cart
Let us come to the part the product pages like to leave out. DMSA has a profile that looks mild in most cases but is real. Most effects appear to be temporary and to resolve. Rarely it can go differently: the toxicological literature describes severe skin and mucous membrane reactions that can require immediate discontinuation. Precisely for that reason these are things you should be able to measure rather than hope for.
What can happen under DMSA
- Liver values: A temporary, usually modest rise in the transaminases is described in up to 60 percent of those treated, as a rule without lasting consequences but in need of monitoring (Bradberry & Vale 2009).
- Gastrointestinal: Nausea, abdominal complaints and diarrhoea are possible, partly because a portion of the active substance remains in the gut.
- Skin: Skin reactions occur in about 6 percent of those treated and are occasionally severe. Severe skin and mucous membrane reactions that can require immediate discontinuation are also described (Bradberry & Vale 2009).
- Blood count: Rarely a fall in the white blood cells, a neutropenia. That is why a blood count belongs before the start and over the course, and immediately in the case of fever or an infection under therapy.
- Trace elements: In humans DMSA is described as mineral-sparing, but high or repeated doses can lower copper and zinc in tissue in animal models.
- Odour: A sulphurous smell of breath and urine is typical of sulphur-containing chelators and in itself not a warning sign.
In lead-burdened rats, DMSA and more fat-soluble related molecules lowered the lead burden, with the fat-soluble ones working better, presumably because DMSA enters cells poorly. Important for safety: at higher or repeated doses, DMSA significantly lowered liver copper. For you this means: repeated DMSA doses can lower copper in tissue, an argument for mineral monitoring (animal data).
Saxena G et al. Toxicology. 2005;214(1-2):39-56. DOI: 10.1016/j.tox.2005.05.026 AnimalWhen DMSA, when something else, when nothing at all
Patients do not need a list of agents, they need a decision logic. The actual medical work does not lie in prescribing a chelator but in the question that comes before it: which metal, which burden, which person. Here the direction, deliberately without a copyable scheme.
Lead in the foreground
Here DMSA is well studied and practical to take orally. With a heavy burden the lowering is a clear mandate, with a moderate one the TLC trial dampens the expectation of an added mental benefit. Context in the lead spoke.
Mercury in the foreground
Here the DMPS path is often more relevant, especially from deeper compartments. The human data on DMSA in mercury are thin, and its inferiority to DMPS rests mainly on animal models.
Vascular and heart question
If the context is cardiovascular, the intravenous EDTA line tends to come into play, with its own controversial evidence.
No clear finding
Without diagnostics, without relevant exposure and without a symptom pattern, the best decision is often to give no chelator and to measure cleanly first. Fatigue, concentration problems and diffuse complaints often have other causes: iron deficiency, a thyroid disorder, a B12 deficiency, disturbed blood sugar, a depression or sleep apnoea. Postponing that work-up in favour of a detox attempt can be costly.
Through the lens of clinical psycho-neuro-immunology, I never look only at one metal but at the whole system: how well the elimination via gut and bile works, how the glutathione balance stands, how resilient liver and kidney are. In this picture a chelator is not a beginning but a building block that only takes effect sensibly once the pathways work through which the body finally gets rid of the mobilized metal.
What makes sense, therefore, is an order that starts with the basics: first measure, then stabilize the elimination pathways and the mineral balance, and only then the question of the right tool. Concrete doses and sequences belong in the individual consultation, not in a blog article, because they only make sense within the overall picture of a single person.
Evidence overview: what we know and what we do not
| Statement | Evidence | Limitation |
|---|---|---|
| DMSA lowers blood lead | RCT, n=780 | Effect real, but limited in time, rebound from the bone |
| Mental benefit at moderate lead burden | Not proven | TLC trial found no advantage at 20 to 44 µg/dL, authors: not indicated in this range |
| DMSA more mineral-sparing than EDTA | Small human studies | Both lower zinc and copper, EDTA the zinc more, high animal doses lower tissue copper |
| Largely extracellular distribution | Human pharmacokinetics | Largely protein-bound, barely cell-penetrating |
| Low brain penetration | Animal model | Only about 8 percent brain mercury reduction in rats |
| Lead before arsenic before mercury | Human (Pb) + animal (Hg) | Mercury inferiority largely from animal data |
| Cutler protocol (frequent low dose) | Hypothesis | No controlled study against the approved dosing |
| Benefit without toxicological indication | Not proven | Cochrane in autism: no evidence, serious events documented |
| Transient transaminase rise | Human data | In up to 60 percent, mostly without consequence, needs monitoring (Bradberry & Vale 2009) |
Classical toxicology gets a great deal right here: it has studied DMSA cleanly in lead poisoning, defined doses and recorded side effects. What the integrative perspective can add is the view of the whole system: mineral balance, elimination pathways, individual resilience and the question of which tool fits which metal. Both together are more than each on its own.
Frequently asked questions about DMSA
Is DMSA the same as DMPS?
Does DMSA bind mercury or lead?
Can you simply buy DMSA capsules and take them yourself?
Does DMSA reach the brain?
What is the Cutler protocol?
What side effects does DMSA have?
Do you lose minerals through DMSA?
What is succimer?
What does the rebound effect mean?
DMSA or DMPS, which fits better?
Is DMSA useful for old amalgam fillings?
What does DMSA detox or DMSA elimination mean?
DMSA in the cluster: fitting deep dives
DMSA is just one tool in a larger picture. These pages belong to it if you want to go deeper.
Heavy metals: the overview
All metals, diagnostics and the logic of a detox
PillarDMPS mobilization test
The intravenous sibling molecule, mercury and diagnostics
EDTA chelation therapy
The second lead chelator, calcium and the vascular question
Side effects & mineral loss
What a chelation therapy can cost and how to counter it
Lead poisoning
Sources, symptoms and detox, the main indication of DMSA
Course of chelation therapy
Duration, steps and what concretely awaits you
Natural detox
Chlorella, coriander, wild garlic, possibilities and limits
Mercury poisoning
Recognize symptoms and detox, when DMPS is more relevant
Scientific sources
- Rogan WJ, Dietrich KN, Ware JH et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med. 2001;344(19):1421-6. DOI: 10.1056/NEJM200105103441902 [RCT, n=780]
- Treatment of Lead-Exposed Children (TLC) Trial Group. Safety and efficacy of succimer in toddlers with blood lead levels of 20-44 microg/dL. Pediatr Res. 2000;48(5):593-9. DOI: 10.1203/00006450-200011000-00007 [RCT, n=780]
- Graziano JH, Lolacono NJ, Meyer P. Dose-response study of oral 2,3-dimercaptosuccinic acid in children with elevated blood lead concentrations. J Pediatr. 1988;113(4):751-7. DOI: 10.1016/s0022-3476(88)80396-2 [RCT, n=21]
- Chisolm JJ. Safety and efficacy of meso-2,3-dimercaptosuccinic acid (DMSA) in children with elevated blood lead concentrations. J Toxicol Clin Toxicol. 2000;38(4):365-75. DOI: 10.1081/clt-100100945 [Clinical study, n=59]
- Bradberry S, Vale A. Dimercaptosuccinic acid (succimer; DMSA) in inorganic lead poisoning. Clin Toxicol (Phila). 2009;47(7):617-31. DOI: 10.1080/15563650903174828 [Systematic review, human]
- Bradberry S, Vale A. A comparison of sodium calcium edetate (edetate calcium disodium) and succimer (DMSA) in the treatment of inorganic lead poisoning. Clin Toxicol (Phila). 2009;47(9):841-58. DOI: 10.3109/15563650903321064 [Systematic comparative review, human]
- de Lange MJ, Piers DA, Kosterink JG et al. Renal handling of technetium-99m DMSA: evidence for glomerular filtration and peritubular uptake. J Nucl Med. 1989;30(7):1219-23. PMID 2544699 [Human pharmacokinetics]
- Fournier L, Thomas G, Garnier R et al. 2,3-Dimercaptosuccinic acid treatment of heavy metal poisoning in humans. Med Toxicol Adverse Drug Exp. 1988;3(6):499-504. DOI: 10.1007/BF03259898 [Case series, n=14, human]
- James S, Stevenson SW, Silove N, Williams K. Chelation for autism spectrum disorder (ASD). Cochrane Database Syst Rev. 2015;(5):CD010766. DOI: 10.1002/14651858.CD010766 [Cochrane systematic review]
- Kostial K, Blanusa M, Piasek M et al. Prolonged oral treatment with two monoesters of meso-2,3-dimercaptosuccinic acid for depleting inorganic mercury retention in suckling rats. Pharmacol Toxicol. 1995;77(3):216-8. DOI: 10.1111/j.1600-0773.1995.tb01015.x [In vivo, rat]
- Bridges CC, Joshee L, Zalups RK. Multidrug resistance proteins and the renal elimination of inorganic mercury mediated by DMPS and DMSA. J Pharmacol Exp Ther. 2007;324(1):383-90. DOI: 10.1124/jpet.107.130708 [In vivo, rat]
- Bridges CC, Joshee L, Zalups RK. Effect of DMPS and DMSA on the placental and fetal disposition of methylmercury. Placenta. 2009;30(9):800-5. DOI: 10.1016/j.placenta.2009.06.005 [In vivo, rat]
- Saxena G, Pathak U, Flora SJS. Beneficial role of monoesters of meso-2,3-dimercaptosuccinic acid in the mobilization of lead and recovery of tissue oxidative injury in rats. Toxicology. 2005;214(1-2):39-56. DOI: 10.1016/j.tox.2005.05.026 [In vivo, rat]
- Bhadauria S, Flora SJS. Response of arsenic-induced oxidative stress, DNA damage, and metal imbalance to combined administration of DMSA and monoisoamyl-DMSA during chronic arsenic poisoning in rats. Cell Biol Toxicol. 2006;23(2):91-104. DOI: 10.1007/s10565-006-0135-8 [In vivo, rat]
- Saric MM, Blanusa M, Juresa D et al. Combined early treatment with chelating agents DMSA and CaDTPA in acute oral cadmium exposure. Basic Clin Pharmacol Toxicol. 2004;94(3):119-23. DOI: 10.1111/j.1742-7843.2004.pto940304.x [In vivo, rat]
- Bridges CC, Joshee L, Zalups RK. MRP2 and the DMPS- and DMSA-mediated elimination of mercury in TR(-) and control rats exposed to thiol S-conjugates of inorganic mercury. Toxicol Sci. 2008;105(1):211-20. DOI: 10.1093/toxsci/kfn107 [In vivo, rat]